CLIFTON SALMON: Open Payments
NPI 1346205507 · HOMER, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$348 in 20 payments from 12 companies in 2025. Trend: 2023 $367 · 2024 $297 · 2025 $348
Food & beverage: $348
| Company | Payments | Amount |
|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $101 |
| Astellas Pharma US Inc | 2 | $38 |
| AstraZeneca Pharmaceuticals LP | 2 | $32 |
| Lilly USA, LLC | 2 | $32 |
| SHIELD THERAPEUTICS INC | 2 | $28 |
| Merck Sharp & Dohme LLC | 1 | $24 |
| Novartis Pharmaceuticals Corporation | 1 | $20 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Exact Sciences Corporation | 1 | $14 |
Products named: Kerendia, Veozah, FARXIGA, MOUNJARO, ACCRUFER, VERQUVO, LEQVIO, GEMTESA.
Industry payments across LA — which companies pay providers there.
